Cresca Capital is a boutique advisory firm focused exclusively on life sciences. We advise biotech investment teams and companies on M&A, fundraising, operations, and strategic partnerships from strategy through close.
Therapeutic Focus
Deep domain expertise at the intersection of life sciences and high-stakes dealmaking.
Cresca Capital was built for biotech founders, investors, and strategics who need a partner that understands both the science and the market dynamics driving value creation in this sector.
Our focus spans the full lifecycle of life sciences companies: from early-stage fundraising and Series A strategy through strategic partnership development, acquisition targeting, and full deal execution.
Partners with MD/PhD and scientific backgrounds who understand your science — not just your financials.
Direct relationships with life sciences VCs, strategic pharma partners, institutional investors, and family offices active in biotech.
Licensed representatives with hands-on experience in PIPE, Follow-On, Private Placement, IPO processes, and M&A execution.
We roll up our sleeves. From diligence to term sheets to closing — we manage the process so you stay focused on your core priorities.
Project-based, ongoing retainer structures, or success fees tailored to your deal timeline, team capacity, and stage of growth.
Services
Institutional-grade M&A and capital raising support without the bulge-bracket overhead.
Target identification, competitive positioning, financial modeling, valuation, deal structuring and closing execution for biotech and pharma companies.
From early through late stage: strategic advice and tactical support throughout the life cycle of the company.
IPO track advisory with strategic positioning, investor communications, IPO syndicate selection, analyst teach in, S-1 drafting and IPO-readiness assessment for private biotechs. PIPE, Follow-On, Private Placement support for public biotechs.
Equity story, investor onboarding, investor and capital markets days, earnings processes, and disclosure protocol build-out for public and IPO-ready companies.
Identify, approach, close and maintain partnerships with pharma. Build your pipeline, lead outreach, negotiate end-to-end.
Financial models, revenue projections, recapitalization structuring, and board materials for biotech-specific metrics.
Build the operating foundation needed to execute growth and development plans. Source and manage key external partners while supporting internal team buildout through targeted search and candidate assessment.
Investor targeting and mapping, competitive landscape analysis, and comparable transaction research that sharpens strategy and supports live fundraising, partnership, and M&A processes.
Professionally designed pitch decks, investor materials, board materials, and data room development to support every stage of engagement with investors, partners, and boards.
Our Partners
Founder & Partner
Heloise is a Registered Representative and Partner at Cresca Capital. She has broad experience across biotech, venture capital, and M&A, working with investors, founders, and operators to structure deals, raise capital, and execute strategic transactions and operational projects. She brings a combination of deal execution experience, an active institutional and biotech investor network, and hands-on operating experience inside boutique advisory, venture capital, and family offices.
Recent engagements include leading diligence on licensing opportunities for a hub-and-spoke biotech company, managing the acquisition of a Stanford IP-backed asset for a biotech investment firm, structuring the launch of a biotech-focused hedge fund, coordinating underwriter selection for a late-stage startup preparing for IPO, and advising several biotech companies on capital markets strategy, and clinical and commercialization planning for clients spanning investment banks, hedge funds, and both clinical and pre-clinical stage companies.
Prior to these roles, Heloise led the diligence on acquisition and investment opportunities at Saltwater Capital, the family office of Ryan Graves, Uber's first CEO. Before that, she sourced and evaluated companies with over $20M in revenue as part of the M&A team at a high-growth unicorn startup with $3B in funding. Earlier in her career, she executed investments as an investor at Secocha Ventures, an early-stage venture capital firm. She started her career as a Summer Analyst at Bank of America and Deutsche Bank.
Heloise holds a Bachelor's degree in Economics-Mathematics from Columbia College, Columbia University in New York.
Principal Advisor
Dr. Meissner is a physician–scientist, biotech investment banker and experienced biotech executive with broad expertise across oncology, immunology, infectious diseases, metabolic disorders and other life sciences sectors. She brings a rare combination of deep scientific knowledge, capital markets insights, broad institutional investor network and a strong track record in corporate strategy.
Previously, Victoria served as Global Head of Investor Relations & Vice President Strategy at BioNTech (BNTX), where she led the transformation of the company's external narrative — successfully repositioning it from a COVID-19 vaccine biotech to a global oncology leader.
Prior to BioNTech, Victoria worked at Jefferies in investment banking advising biotech clients on financings (PIPE, Follow-On, Private Placement, IPO) and M&A.
Earlier, Victoria took her academic journey to Chicago after earning her M.D. from the Medical University of Vienna. Her Ph.D. research at the University of Illinois Hospital at Chicago, div. of Transplant Surgery, focused on diabetes and pancreatic islet transplantation.
Dr. Meissner's core strengths are her extensive knowledge of biotech capital markets and her ability to leverage her subject matter expertise to translate deep scientific insight and understanding of the competitive landscape into actionable corporate strategy and compelling external positioning, often driving meaningful shifts in valuation and market perception.
Contact
Whether you're a biotech founder preparing for your next round, an investor seeking deal flow or diligence support, or a strategic exploring acquisition opportunities — let's talk.
Start a ConversationCresca Capital · Life Sciences Capital Markets Advisory
Securities are offered through Finalis Securities LLC Member FINRA / SIPC. Cresca Capital is not a registered broker-dealer, and Finalis Securities LLC and Cresca Capital are separate, unaffiliated entities. Finalis Securities LLC, Office of Supervisory Jurisdiction is located at 450 Lexington Ave, New York, NY 10017, 800-962-0418.
crescacap.com (the “Cresca Capital Website”) is a website operated by Cresca Capital. This website is for informational purposes only, is not an offer, solicitation, recommendation, or commitment for any transaction or to buy or sell any security or other financial product, and is not intended as investment advice or as a confirmation of any transaction. Products and services on this website may not be available for residents of certain jurisdictions. Please consult with a Finalis Securities’ registered representative regarding the product or service in question for further information. Investments involve risk and are not guaranteed to appreciate. Any market price, indicative value, estimate, view, opinion, data, or other information herein is not warranted as to completeness or accuracy, is subject to change without notice, and Cresca Capital along with Finalis Securities LLC accepts no liability for its use or to update it or keep it current.
Investing in private placements involves a high degree of risk. These investments may be illiquid, speculative, and subject to substantial restrictions on transferability. Investors may lose all or part of their investment and should only invest capital they can afford to lose. Prospective investors should conduct their own due diligence and consult with their legal, tax, and financial advisors prior to making any investment decision. For your reference, Finalis’ Form CRS describes the services that we provide, how we are compensated, and other important information about Finalis Securities LLC.